MindMed today announced the ethics committee approval of a Phase 1 clinical trial evaluating the acute effects of mescaline, with varying doses employed. The company hopes to start the trial at University Hospital Basel’s Liechti Lab later this month. Dr. Matthias Liechti commented, “This study will, we believe, provide the first modern research data on mescaline regarding dosing and mechanism of…


Previous articleDr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer
Next articleAccomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs